Transcatheter Valve Therapy (TVT): The Structural Heart Summit convenes leaders in the field to present three days of world-class education and global networking.
Professional Practice Gap
The maturation of transcatheter aortic valve replacement (TAVR) and the rapid adoption of transcatheter mitral and tricuspid therapies have changed the treatment landscape, expanding options for patients with structural heart disease (SHD). The central mission of TVT is to provide health professionals involved in care of SHD patients comprehensive insight and updates, annually, on a rapidly evolving field of minimally invasive treatment options for patients with structural heart disease.
Treatment of structural heart disease is truly multidisciplinary, integrating noninvasive cardiac imaging, surgical therapies, heart failure management, and novel transcatheter approaches — underscoring the importance of professional continuing education.
By the end of this course, participants should be able to:
- Discuss the evaluation and management of patients with valvular and structural heart disease.
- Assess the imaging modalities available for diagnosing valvular and structural heart disease.
- Describe current and future therapeutic options for valvular and structural heart disease.
- Understand the skills necessary to perform transcatheter valve therapies, left atrial appendage (LAA) closure, and patent foramen ovale (PFO) closure.
Who Should Attend TVT?
TVT is designed for a multidisciplinary audience that includes anyone interested in the treatment of valvular and structural heart disease. This includes:
- Biomedical engineers.
- Cardiac and vascular surgeons.
- Cardiac imaging specialists (especially echo and CT).
- Cath lab technologists.
- Clinical cardiologists.
- Heart failure specialists.
- Interventional cardiologists.
- Medical device experts.
- Nurse practitioners.
- Physician assistants.
- Research scientists.